Alzheimer's research tests from Lifescreen:
This article was originally published in Clinica
Executive Summary
Lifescreen (UK) has launched two new products for use in Alzheimer's disease research. The first is an ELISA that can detect as little as 3pg of b-amyloid peptide. The assay comes in a 96-well format and uses a fluorescent substrate to achieve high sensitivity, the company says. The second product is the Synthaloid AD Drug Discovery System for screening products that modify b-amyloid deposition. It uses a b-amyloid polymer matrix to mimic the behaviour of b-amyloid in the brain.
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.